

## **Supplementary Information for**

### **Low Valency Display of Glycomimetic Inhibitor of Adhesion of Pathogenic *Candida albicans* to Human Buccal Epithelial Cells**

Harlei Martin <sup>1</sup>, Hannah Masterson <sup>2</sup>, Kevin Kavanagh <sup>2,3,\*</sup> and Trinidad Velasco-Torrijos <sup>1,3,\*</sup>

1- Department of Chemistry, Maynooth University, Maynooth, Co. Kildare, Ireland

2- Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland

3- The Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co. Kildare, Ireland

## **Content**

1.1. <sup>1</sup>H NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl-β-*D*-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-*N''*-(2-bromoacetamido)-5-aminobenzene-1,3-dicarboxamide (**7**)

1.2. <sup>13</sup>C NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl-β-*D*-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-*N''*-(2-bromoacetamido)-5-aminobenzene-1,3-dicarboxamide (**7**)

1.3. <sup>1</sup>H NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl-β-*D*-galactopyranosyl-1,2,3-triazol-4-ylmethyl amide)-*N''*-(2-azidoacetamido)-5-aminobenzene-1,3-dicarboxamide (**8**)

1.4. <sup>13</sup>C NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl-β-*D*-galactopyranosyl-1,2,3-triazol-4-ylmethyl amide)-*N''*-(2-azidoacetamido)-5-aminobenzene-1,3-dicarboxamide (**8**)

1.5. <sup>1</sup>H NMR of 2-[2-(2-Propargyloxyethoxy)ethoxy]ethanol (**9**)

1.6. <sup>1</sup>H NMR of 2-(2-(2-Propargyloxyethoxy)ethoxy)ethyl-4-methylbenzenesulfonate (**10**)

1.7. <sup>1</sup>H NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl-β-*D*-galactopyranosyl-1,2,3-triazol-4-ylmethyl amide)-*N''*-(2-4-((2-(2-(2-(4-methylbenzenesulfonate)ethoxy)ethoxy)ethoxy) methyl)-1*H*-1,2,3-triazol-1-yl)acetamido)-5-aminobenzene-1,3-dicarboxamide (**11**)

1.8. <sup>13</sup>C NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl-β-*D*-galactopyranosyl-1,2,3-triazol-4-ylmethyl amide)-*N''*-(2-4-((2-(2-(2-(4-methylbenzenesulfonate)ethoxy)ethoxy)ethoxy) methyl)-1*H*-1,2,3-triazol-1-yl)acetamido)-5-aminobenzene-1,3-dicarboxamide (**11**)

1.9. <sup>1</sup>H NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl-β-*D*-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-*N''*-(2-4-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-1*H*-1,2,3-triazol-1-yl)acetamido)-5-aminobenzene-1,3-dicarboxamide (**12**)

1.10. <sup>13</sup>C NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl-β-*D*-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-*N''*-(2-4-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-1*H*-1,2,3-triazol-1-yl)acetamido)-5-aminobenzene-1,3-dicarboxamide (**12**)

1.11. <sup>1</sup>H NMR of *tert*-butyl (4,8,12,16-tetra-*aza*)(5,9,13,17-tetra-*oxo*)(4,8,12,16-tetra-*N*-propargyl)octadecanoate (**2**)

1.12.  $^{13}\text{C}$  NMR of tert-butyl (4,8,12,16-tetra-aza)(5,9,13,17-tetra-oxo)(4,8,12,16-tetra-N-propargyl) octadecanoate (**2**)

1.13.  $^1\text{H}$  NMR of Acetylated Tetravalent  $\beta$ -Peptoid Glycocluster (**13**)

1.14.  $^{13}\text{C}$  NMR of Acetylated Tetravalent  $\beta$ -Peptoid Glycocluster (**13**)

1.15.  $^1\text{H}$  NMR of Tetravalent  $\beta$ -Peptoid Glycocluster (**3**)

1.16.  $^{13}\text{C}$  NMR of Tetravalent  $\beta$ -Peptoid Glycocluster (**3**)


1.17.  $^1\text{H}$  NMR of 2,6,10,14-tetraoxo-3,7,11,15-tetrakis((1-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactopyranosyl -1H-1,2,3-triazol-4-yl)methyl)-3,7,11,15-tetraazaoctadecan-18-oic acid (**14**)

1.18.  $^{13}\text{C}$  NMR of 2,6,10,14-tetraoxo-3,7,11,15-tetrakis((1-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactopyranosyl -1H-1,2,3-triazol-4-yl)methyl)-3,7,11,15-tetraazaoctadecan-18-oic acid (**14**)


1.19.  $^1\text{H}$  NMR of 2,6,10,14-tetraoxo-3,7,11,15-tetrakis((1-( $\beta$ -D-galactopyranosyl -1H-1,2,3-triazol-4-yl)methyl)-3,7,11,15-tetraazaoctadecan-18-oic acid (**15**)

1.20.  $^{13}\text{C}$  NMR of 2,6,10,14-tetraoxo-3,7,11,15-tetrakis((1-( $\beta$ -D-galactopyranosyl -1H-1,2,3-triazol-4-yl)methyl)-3,7,11,15-tetraazaoctadecan-18-oic acid (**15**)


1.1.  $^1\text{H}$  NMR of *N, N'*-di-(2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-*N''*-(2-bromoacetamido)-5-aminobenzene-1,3-dicarboxamide (**7**)




1.2.  $^{13}\text{C}$  NMR of *N, N'*-di-(2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-*N''*-(2-bromoacetamido)-5-aminobenzene-1,3-dicarboxamide (**7**)




1.3.  $^1\text{H}$  NMR of *N,N'*-di-(2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl-1,2,3-triazol-4-ylmethyl amide)-*N''*-(2-azidoacetamido)-5-aminobenzene-1,3-dicarboxamide (**8**)




1.4.  $^{13}\text{C}$  NMR of *N,N'*-di-(2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl-1,2,3-triazol-4-ylmethyl amide)-*N''*-(2-azidoacetamido)-5-aminobenzene-1,3-dicarboxamide (**8**)




### 1.5. <sup>1</sup>H NMR of 2-[2-(2-Propargyloxyethoxy)ethoxy]ethanol (**9**)




### 1.6. <sup>1</sup>H NMR of 2-(2-(2-Propargyloxyethoxy)ethoxy)ethyl-4-methylbenzenesulfonate (**10**)




1.7.  $^1\text{H}$  NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl-1,2,3-triazol-4-ylmethyl amide)-*N''*-(2-4-((2-(2-(4-methylbenzenesulfonate)ethoxy)ethoxy)ethoxy) methyl)-1*H*-1,2,3-triazol-1-yl)acetamido)-5-aminobenzene-1,3-dicarboxamide (**11**)




1.8.  $^{13}\text{C}$  NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl-1,2,3-triazol-4-ylmethyl amide)-*N''*-(2-4-((2-(2-(4-methylbenzenesulfonate)ethoxy)ethoxy)ethoxy) methyl)-1*H*-1,2,3-triazol-1-yl)acetamido)-5-aminobenzene-1,3-dicarboxamide (**11**)




1.9.  $^1\text{H}$  NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-*N''*-(2-4-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-1*H*-1,2,3-triazol-1-yl)acetamido)-5-aminobenzene-1,3-dicarboxamide (**12**)




1.10.  $^{13}\text{C}$  NMR of *N*, *N'*-di-(2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-*N''*-(2-4-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-1*H*-1,2,3-triazol-1-yl)acetamido)-5-aminobenzene-1,3-dicarboxamide (**12**)



1.11.  $^1\text{H}$  NMR of *tert*-butyl (4,8,12,16-tetra-aza)(5,9,13,17-tetra-oxo)(4,8,12,16-tetra-*N*-propargyl) octadeconoate (**2**)




1.12.  $^{13}\text{C}$  NMR of *tert*-butyl (4,8,12,16-tetra-aza)(5,9,13,17-tetra-oxo)(4,8,12,16-tetra-*N*-propargyl) octadeconoate (**2**)







### 1.13. $^1\text{H}$ NMR of Acetylated Tetravalent $\beta$ -Peptoid Glycocluster (**13**)




### 1.14. $^{13}\text{C}$ NMR of Acetylated Tetravalent $\beta$ -Peptoid Glycocluster (**13**)




### 1.15. $^1\text{H}$ NMR of Tetravalent $\beta$ -Peptoid Glycocluster (**3**)




### 1.16. $^{13}\text{C}$ NMR of Tetravalent $\beta$ -Peptoid Glycocluster (**3**)




1.17.  $^1\text{H}$  NMR of 2,6,10,14-tetraoxo-3,7,11,15-tetrakis((1-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactopyranosyl-1H-1,2,3-triazol-4-yl)methyl)-3,7,11,15-tetraazaoctadecan-18-oic acid (**14**)



1.18.  $^{13}\text{C}$  NMR of 2,6,10,14-tetraoxo-3,7,11,15-tetrakis((1-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactopyranosyl-1H-1,2,3-triazol-4-yl)methyl)-3,7,11,15-tetraazaoctadecan-18-oic acid (**14**)



1.19.  $^1\text{H}$  NMR of 2,6,10,14-tetraoxo-3,7,11,15-tetrakis((1-( $\beta$ -D-galactopyranosyl)-1H-1,2,3-triazol-4-yl)methyl)-3,7,11,15-tetraazaoctadecan-18-oic acid (**15**)



1.20.  $^{13}\text{C}$  NMR of 2,6,10,14-tetraoxo-3,7,11,15-tetrakis((1-( $\beta$ -D-galactopyranosyl)-1H-1,2,3-triazol-4-yl)methyl)-3,7,11,15-tetraazaoctadecan-18-oic acid (**15**)

